bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice
- PMID: 1691092
- PMCID: PMC551781
- DOI: 10.1002/j.1460-2075.1990.tb08212.x
bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice
Abstract
The chromosome translocation forming the hybrid bcr-abl gene is thought to be the initiating event in chronic myeloid leukaemia (CML) and some cases of acute lymphoblastic leukaemia. To assess the impact of bcr-abl upon haemopoiesis, lethally irradiated mice were reconstituted with bone marrow cells enriched for cycling stem cells and infected with a bcr-abl bearing retrovirus. The mice developed several fatal diseases with abnormal accumulations of macrophage, erythroid, mast and lymphoid cells, and marked strain differences in disease distribution and kinetics. Some mice exhibited more than one neoplastic cell type and, in some instances, these were clonally related, indicating that a progenitor or stem cell had been transformed. While classical CML was not observed, the macrophage tumours were accompanied by a mild CML-like syndrome, probably due to myeloid growth factor production by tumour cells. The erythroid and mast cell diseases were rarely transplantable, in contrast to the macrophage tumours and lymphomas, but all disease types displayed limited clonality. These results establish that bcr-abl confers a proliferative advantage on diverse haemopoietic cells but complete transformation probably involves additional genetic changes.
Similar articles
-
Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.Blood. 1998 Nov 15;92(10):3829-40. Blood. 1998. PMID: 9808576
-
Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL.Blood. 2001 Mar 1;97(5):1442-50. doi: 10.1182/blood.v97.5.1442. Blood. 2001. PMID: 11222392
-
bcr-abl-Induced cell lines can switch from mast cell to erythroid or myeloid differentiation in vitro.Blood. 1992 Mar 1;79(5):1271-81. Blood. 1992. PMID: 1536951
-
The molecular biology of chronic myeloid leukaemia.Leukemia. 1996 May;10(5):751-6. Leukemia. 1996. PMID: 8656667 Review.
-
Malignant transformation by abl and BCR/ABL.Cancer Treat Res. 1992;63:167-92. doi: 10.1007/978-1-4615-3088-6_8. Cancer Treat Res. 1992. PMID: 1363357 Review. No abstract available.
Cited by
-
Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia.Cell Rep. 2013 Oct 17;5(1):51-60. doi: 10.1016/j.celrep.2013.08.037. Epub 2013 Oct 3. Cell Rep. 2013. PMID: 24095735 Free PMC article.
-
Mouse models as tools to understand and study BCR-ABL1 diseases.Am J Blood Res. 2011;1(1):65-75. Epub 2011 Jun 7. Am J Blood Res. 2011. PMID: 22432067 Free PMC article.
-
Recurrent gene fusions in prostate cancer.Nat Rev Cancer. 2008 Jul;8(7):497-511. doi: 10.1038/nrc2402. Epub 2008 Jun 19. Nat Rev Cancer. 2008. PMID: 18563191 Free PMC article. Review.
-
Differences in oncogenic potency but not target cell specificity distinguish the two forms of the BCR/ABL oncogene.Mol Cell Biol. 1991 Sep;11(9):4710-6. doi: 10.1128/mcb.11.9.4710-4716.1991. Mol Cell Biol. 1991. PMID: 1875948 Free PMC article.
-
Bcr-Abl is a "molecular switch" for the decision for growth and differentiation in hematopoietic stem cells.Int J Hematol. 2002 Jul;76(1):35-43. doi: 10.1007/BF02982716. Int J Hematol. 2002. PMID: 12138893 Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous